It has all the ingredients.
If you look at other pre-revenue medtech listed companies, most of them trade for high valuations due to the difficulty bringing a product to market.
EMV is a software play as much as a hardware play, the image processing algorithms and artificial intelligence software could be used with other applications in the future.
This will be trading with a dollar sign in front of it by the end of year as results from clinical trials are delivered. Plenty of upside.
It has all the ingredients. If you look at other pre-revenue...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.93 |
Change
0.040(2.12%) |
Mkt cap ! $174.4M | |||
| Open | High | Low | Value | Volume |
| $1.91 | $1.95 | $1.91 | $140.5K | 72.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2067 | $1.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.93 | 4701 | 1 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| EMV (ASX) Chart |
